IOVANCE BIOTHERAPEUTICS INC (IOVA)
Health Care · Biotechnology / Oncology · NASDAQ
Iovance is a pioneer in tumor infiltrating lymphocyte (TIL) cell therapy, offering the first one-time, individualized T cell treatment for advanced solid tumor cancers.
What IOVANCE BIOTHERAPEUTICS INC does
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. Its primary product is Amtagvi (lifileucel), a one-time individualized T cell therapy for advanced melanoma, which is administered in conjunction with Proleukin (aldesleukin). The company utilizes proprietary, centralized manufacturing processes to multiply patient-derived T cells to treat various solid tumor indications.
Themes: cell therapy, immunotherapy, oncology, solid tumors, personalized medicine
Fundamentals
- Price$8.29 as of 2026-08-21 close
- Market cap$3.8B as of 2026-08-21
- 1-year return+226.4% 2025-08-21 close $2.54 → 2026-08-21 close $8.29
- P/En/a negative earnings
- Net margin-89.1% as of 2026-08-24
- Gross margin+48.4% as of 2026-08-24
- ROE-40.5% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+34.5% as of 2026-08-24
- Revenue CAGR (3y)+1388.7% SEC XBRL
- Beta0.85 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How IOVA compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
IOVA is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
68.2 #17 of 1,704 scored · #7 of 240 in Health Care
Trend 92nd: it is trading 64.4% above its 50-day average, the short-term trend line; volume and participation 71st: trading volume is about normal versus its 30-day average; weakest is setup 42nd: day-to-day price swings are unusually wide versus its own recent history (wider than about 96% of the past ~6 months).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How IOVANCE BIOTHERAPEUTICS INC looks technically
IOVANCE BIOTHERAPEUTICS INC (IOVA) is trading 131.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 146 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70). It made a new 20-day high about 2 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 131.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +131.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.04 | $5.04 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.57 | $3.57 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 3.96. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 146 trading days ago — a "golden cross", a bullish long-term signal | 146 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with buyers in control | 44.8 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70) | 72.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($4.29 to $9.36) — its "stochastic" reading is 79 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 78.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.36 | $9.36 |
|---|---|---|
| From the 52-week high | it is 11.4% below its 52-week high (its highest price of the past year) | -11.4% |
| Above the 52-week low | it is 371.0% above its 52-week low (its lowest price of the past year) | +371.0% |
| Below the 52-week high | it is 11.4% below its highest point of the past year | 11.4% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $165.00 (set on 2011-06-07) | $165.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.81 to $8.99), and it has given back only a small part of its rise from last year’s low — 10% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.32 to $4.55. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 9.8% |
| From the all-time high | it is 95.0% below its all-time high | -95.0% |
| Nearest price level | it is trading 14.9% above a support level at $7.05 — a price it turned at twice since 2024-12-18, most recently on 2024-12-30. Since 2024-08-21 it has 12 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -14.9% |
| All-time low | its lowest closing price on record is $1.00 (set on 2013-04-12) | $1.00 |
| Above the all-time low | it is 729.0% above its all-time low | +729.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 96% of the past ~6 months) | 96th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6344 between its high and its low — about 7.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6344 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.17 and $8.93 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.17 – $6.05 – $8.93 |
| Typical daily range (% of price) | its price moves about 7.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.7% |
| Stretch from the 200-day average | it is trading 7.4 daily ranges above its 200-day average price (131.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.43× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.2% since the prior reading | +1.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Open gap | it gapped 2.4% above the previous close 2 sessions ago and has not traded back through the level it left behind at 7.03 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.4% |
| Gap filled | a 2.0% gap down opened on 2026-08-17 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 48.9 percentage points (the stock gained 51.3% while the market gained 2.3%) | +49.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 121.0 percentage points (the stock gained 124.1% while the market gained 3.1%) | +121.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 177.8 percentage points (the stock gained 188.9% while the market gained 11.1%) | +177.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 205.9 percentage points (the stock gained 226.4% while the market gained 20.5%) | +205.9% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 87% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.8% of the share price. | +87.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 96% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.22 — a volume-weighted average of daily closes over 154 sessions, not a true tick-by-tick VWAP. | +96.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 16% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $7.14 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +16.0% |
Price levels it has turned at before
IOVA last closed at $8.29 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.05 | Support | 14.9% below the last close | turned there twice · 2024-12-18 to 2024-12-30 |
| $5.61 | Support | 32.3% below the last close | turned there three times · 2025-01-21 to 2026-07-22 |
| $4.55 | Support | 45.1% below the last close | turned there twice · 2026-06-05 to 2026-07-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $3.96.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $5.84 and $7.00 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $3.96.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.67 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$9.33 range $4.00 – $14.00; median $9.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IOVA
- Consensus EPS estimate-$0.089 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on the commercial success of a single primary product (Amtagvi) in a competitive oncology market.","Operational risks associated with complex, centralized manufacturing and delivery of individualized cell therapies.","Requirement for continued regulatory approvals and market access across international jurisdictions."]
What changed in the latest 10-Q
AI-assisted comparison of IOVA's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) adds: 'Potential approvals are pending in Australia in the first half of 2026 and Switzerland in 2027.'
- Newer filing (2026-05-07) adds: 'In the United Kingdom, or UK, we withdrew our initial MAA in May 2026 and will resubmit the MAA with additional information for expedited review in 2026.'
- Newer filing (2026-05-07) adds: 'We have commenced a registrational trial in previously treated advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, and plan to engage with the FDA for an expedited path to accelerated approval.'
- Newer filing (2026-05-07) adds section: 'Educating, training, and collaborating with healthcare professionals, or HCPs, who will be administering our product at academic and community authorized treatment centers, or ATCs, as well as community oncologists and advocacy groups who will refer patients to our ATCs;'
- Removed:
- Older filing (2025-11-06) states: 'An MAA was submitted to the Medicines and Healthcare Products Regulatory Agency in the UK and is on track for potential approval and launch in the first half of 2026.' This specific timeline statement is not present in newer filing.
- Older filing (2025-11-06) describes: 'we are investigating TIL monotherapies for patients previously treated with standard of care therapies and TIL cell therapy in combination with standard of care therapies for patients in earlier treatment settings.' Newer filing does not include this specific language.
- Older filing (2025-11-06) references: 'we are also developing next generation therapies, such as genetically modified TIL cell therapy and next generation cytokines.' Newer filing does not include this specific reference.
- Reworded:
- Older filing (2025-11-06) overview begins: 'We are a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer by harnessing the human immune system's ability...' Newer filing (2026-05-07) simplifies to: 'We are a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer. Our mission is to be the global leader...'
- Older filing (2025-11-06) states Amtagvi is 'the first and the only one-time, individualized T cell therapy to receive U.S. Food and Drug Administration, or the FDA, approval for a solid tumor cancer.' Newer filing (2026-05-07) states: 'the first one-time, individualized T cell therapy for a solid tumor cancer'—removing 'and the only' qualifier.
- Older filing (2025-11-06) uses phrase: 'Following U.S. FDA approval of Amtagvi ® for the treatment of patients with post-anti-PD-1 advanced melanoma on February 16, 2024, our top priority is continuing to leverage our experienced marketing...' Newer filing (2026-05-07) restructures without referencing the approval date within the same section.
- Older filing (2025-11-06) references 'supporting operations and patient enrollment at authorized treatment centers' while newer filing (2026-05-07) adds specificity: 'Providing operational and patient support at ATCs in the U.S. and onboarding ATCs in preparation for anticipated regulatory approvals'
- Notes:
- The newer filing text appears truncated at 'To date, more than 1,500 patients h' making full comparison of the manufacturing section incomplete.
- The older filing text also appears truncated at 'operational excellence in launch execution, commercial manufacturing, and delivery of th' limiting comparison of complete strategic priority statements.
Risk Factors
- Removed:
- Removed from newer filing (2026-05-07): Statement 'We have marked with an asterisk (*) those risk factors below that reflect a substantive change from the risk factors included in our Annual Report on Form 10-K filed with the SEC on February 27, 2025.' that appeared in older filing (2025-11-06)
- Reworded:
- Newer filing (2026-05-07) removed asterisks (*) marking substantive changes that were present throughout the older filing (2025-11-06), including asterisks on: 'Raising additional capital may cause dilution...' risk factor; 'Cell-based therapies and biologics rely on the availability...' risk factor; 'We will need to grow the size and capabilities...' risk factor; 'We may be unable to successfully or sufficiently expand our manufacturing capacity...' risk factor; and 'We rely on and collaborate with governmental, academic, and corporate partners...' risk factor
- Newer filing (2026-05-07) changed 'and may be incorrect or unreliable' to 'may be incorrect or unreliable' in the risk factor regarding collaboration with governmental, academic, and corporate partners (removed 'and' conjunction)
- Notes:
- Both filings appear truncated at the end of the Risk Factors Summary section, so full comparison of complete risk factor listings is not possible
- The older filing explicitly notes which risk factors were marked with asterisks to indicate substantive changes from a prior Form 10-K; the newer filing removes this marking system entirely
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for IOVA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding IOVA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 52,440,459
- Reported value $184,066,010
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
IOVA had 99,975,709 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
IOVA had 22.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.28 days to cover at the same settlement.
- Reported short interest (shares) 99,975,709
- Short interest (% of shares outstanding) 22.1%
- Prior settlement (shares) 99,892,938
- Reported change 0.08%
- Days to cover (reported) 6.28
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bristol Myers Squibb (BMY)
- Merck (MRK)
- Novartis (NVS)
- Gilead Sciences (GILD)
- Adaptimmune Therapeutics (ADAP)
- Instil Bio (TIL)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IOVA vs…
IOVANCE BIOTHERAPEUTICS INC is found in…
IOVA ranks in…
Frequently asked questions
What does IOVANCE BIOTHERAPEUTICS INC (IOVA) do?
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. Its primary product is Amtagvi (lifileucel), a one-time individualized T cell therapy for advanced melanoma, which is administered in conjunction with Proleukin (aldesleukin).
What sector is IOVANCE BIOTHERAPEUTICS INC (IOVA) in?
IOVANCE BIOTHERAPEUTICS INC (IOVA) is classified in the Health Care sector. Its industry is Biotechnology / Oncology. It trades on NASDAQ.
Who are IOVANCE BIOTHERAPEUTICS INC's (IOVA) competitors?
Notable peers of IOVANCE BIOTHERAPEUTICS INC (IOVA) include Bristol Myers Squibb, Merck, Novartis, Gilead Sciences and Adaptimmune Therapeutics. This peer set is informational only — not financial advice.
Is IOVANCE BIOTHERAPEUTICS INC (IOVA) overbought or oversold right now?
IOVANCE BIOTHERAPEUTICS INC (IOVA) is currently in overbought territory (its 14-day RSI is 72, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IOVA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.